地拉罗司作用及价格

(Enrig) What are its functions and prices? Let's take a look. The U.S. Food and Drug Administration (FDA) approved a new indication for deferasirox (Enriga) on January 23 for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT).

To study the iron-removing efficacy and safety of deferasirox (Enrige) in patients with aplastic anemia (AA) associated with iron overload. The iron-removing efficacy of 64 AA patients with iron overload after 12 months of deferasirox treatment was analyzed, and the safety was evaluated. Results The starting dose of deferasirox for all patients was 20.0 mg·kg-1·d-1, and the average dose was (18.6±3.60) mg·kg-1·d-1. After 12 months of treatment, the median serum ferritin (SF) level dropped from the baseline of 4 924 (2 718 to 6 765) μg/L (64 cases) to 3 036 (1 474 to 5 551) μg/L (23 cases), a decrease of 38%, and the median SF reduction was 651 (126 to 2 125) μg/L; the median SF level of 23 patients who completed 12 months of treatment dropped from the baseline of 5 271 (3 420 ~ 8 278) μg/L to 3 036 (1 474 ~ 5 551) μg/L, a decrease of 42%, and the median SF reduction was 1 167 (580 ~ 4 806) μg/L.

The new indication for deferasirox was approved by the FDA through the accelerated approval process, which allows patients to have early access to this promising new drug to treat serious or life-threatening diseases, while the company conducts additional studies to ensure the clinical effectiveness of deferasirox (Enrige).

Deferasirox (Enrego) from Novartis, Switzerland, has a specification of 400mg*30 tablets/box, and the price is about $700. The specifications of India (Enrige) are 500*30 pieces/box, and the price is about 500$. Due to exchange rate fluctuations, prices are uncertain. Please consult Medical Travel for specific prices.

Related hot article recommendations: